NDM-12, a novel New Delhi metallo-β-lactamase variant from a carbapenem-resistant Escherichia coli clinical isolate in Nepal

Tatsuya Tada; Basudha Shrestha; Tohru Miyoshi-Akiyama; Kayo Shimada; Hiroshi Ohara; Teruo Kirikae; Bharat M Pokhrel

doi:10.1128/AAC.03355-14

NDM-12, a novel New Delhi metallo-β-lactamase variant from a carbapenem-resistant Escherichia coli clinical isolate in Nepal

Antimicrob Agents Chemother. 2014 Oct;58(10):6302-5. doi: 10.1128/AAC.03355-14. Epub 2014 Aug 4.

Authors

Tatsuya Tada¹, Basudha Shrestha², Tohru Miyoshi-Akiyama¹, Kayo Shimada¹, Hiroshi Ohara³, Teruo Kirikae⁴, Bharat M Pokhrel²

Affiliations

¹ Department of Infectious Diseases, Research Institute, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan.
² Department of Microbiology, Institute of Medicine, Tribhuvan University, Maharajgunj, Kathmandu, Nepal.
³ Department of International Medical-Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan.
⁴ Department of Infectious Diseases, Research Institute, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan tkirikae@ri.imcj.go.jp.

Abstract

A novel New Delhi metallo-β-lactamase variant, NDM-12, was identified in a carbapenem-resistant Escherichia coli clinical isolate obtained from a urine sample from a patient in Nepal. NDM-12 differed from NDM-1 by two amino acid substitutions (M154L and G222D). The enzymatic activities of NDM-12 against β-lactams were similar to those of NDM-1, although NDM-12 showed lower kcat/Km ratios for all β-lactams tested except doripenem. The blaNDM-12 gene was located in a plasmid of 160 kb.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / pharmacology*
Carbapenems / pharmacology*
Escherichia coli / drug effects*
Escherichia coli / enzymology*
Microbial Sensitivity Tests
Nepal
beta-Lactamases / genetics
beta-Lactamases / metabolism*

Substances

Anti-Bacterial Agents
Carbapenems
beta-Lactamases